Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies - Angiolillo, D J; Gibson, C M; Cheng, S; Ollier, C; Nicolas, O; Bergougnan, L; Perrin, L; LaCreta, F P; Hurbin, F; Dubar, M (Clinical pharmacology and therapeutics, 2011)
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology; Adult; Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - pharmacology; Female; Half-Life; Humans; Male; Middle Aged; Omeprazole - administration & dosage; Omeprazole - adverse effects; Omeprazole - pharmacology; Platelet Activation - drug effects; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - blood; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Aggregation Inhibitors - pharmacology; Prodrugs - adverse effects; Prodrugs - pharmacokinetics; Prodrugs - pharmacology; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - pharmacology; Ticlopidine - analogs & derivatives; Ticlopidine - blood; Ticlopidine - pharmacokinetics; Ticlopidine - pharmacology; Young Adult